174 related articles for article (PubMed ID: 12168868)
1. Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions.
Mitselou A; Vougiouklakis TG; Peschos D; Dallas P; Boumba VA; Agnantis NJ
Anticancer Res; 2002; 22(3):1777-80. PubMed ID: 12168868
[TBL] [Abstract][Full Text] [Related]
2. Epithelial membrane antigen and S-100 protein expression in benign and malignant papillary thyroid neoplasms.
Kilicarslan B; Pesterelli EH; Oren N; Sargin FC; Karpuzoglu G
Adv Clin Path; 2000 Oct; 4(4):155-8. PubMed ID: 11436147
[TBL] [Abstract][Full Text] [Related]
3. The immunohistochemical localization of S100 in the diagnosis of papillary carcinoma of the thyroid.
McLaren KM; Cossar DW
Hum Pathol; 1996 Jul; 27(7):633-6. PubMed ID: 8698304
[TBL] [Abstract][Full Text] [Related]
4. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
6. p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma.
Erickson LA; Yousef OM; Jin L; Lohse CM; Pankratz VS; Lloyd RV
Mod Pathol; 2000 Sep; 13(9):1014-9. PubMed ID: 11007042
[TBL] [Abstract][Full Text] [Related]
7. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
Rabban JT; Koerner FC; Lerwill MF
Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
[TBL] [Abstract][Full Text] [Related]
8. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
9. Cribriform-morular variant of papillary carcinoma: the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma. A case report with clinical and molecular genetic correlation.
Ng SB; Sittampalam K; Goh YH; Eu KW
Pathology; 2003 Feb; 35(1):42-6. PubMed ID: 12701683
[TBL] [Abstract][Full Text] [Related]
10. p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin.
Reis-Filho JS; Preto A; Soares P; Ricardo S; Cameselle-Teijeiro J; Sobrinho-Simões M
Mod Pathol; 2003 Jan; 16(1):43-8. PubMed ID: 12527712
[TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical analysis of malignant tumors of the thyroid gland using 6 relevant markers].
Brasanac D; Jancić-Zgurics M; Janković R; Tatić S
Srp Arh Celok Lek; 1993; 121(3-7):70-3. PubMed ID: 7716641
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.
Sahoo S; Hoda SA; Rosai J; DeLellis RA
Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686
[TBL] [Abstract][Full Text] [Related]
13. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.
Casey MB; Lohse CM; Lloyd RV
Endocr Pathol; 2003; 14(1):55-60. PubMed ID: 12746563
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
15. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.
Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT
Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
[TBL] [Abstract][Full Text] [Related]
17. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical study in thyroid cancer.
Beltrami CA; Barbatelli G; Criante P; Paliaga A; Amadi CE
Appl Pathol; 1987; 5(4):229-45. PubMed ID: 2446641
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of pl30cas in papillary thyroid carcinoma.
Dilek FH; Aktepe F; Sahin DA; Topak N; Dilek ON
Int Surg; 2008; 93(3):175-80. PubMed ID: 18828274
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions.
Saiz AD; Olvera M; Rezk S; Florentine BA; McCourty A; Brynes RK
J Pathol; 2002 Oct; 198(2):157-62. PubMed ID: 12237874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
